Workflow
Genprex(GNPX)
icon
Search documents
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes
Prnewswire· 2024-09-23 13:29
Core Insights - Genprex, Inc. is focused on developing innovative gene therapies for cancer and diabetes, with recent highlights from CEO Ryan Confer in CEO/CFO Magazine [1][2] Group 1: Gene Therapy Programs - The company is advancing its gene therapy approaches in oncology and diabetes, with updates on the Acclaim clinical trials for lung cancer and the introduction of biomarker testing in its oncology program [2][4] - Genprex's lead product candidate, Reqorsa® Gene Therapy, is under evaluation in two clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [4] Group 2: Diabetes Program - Genprex plans to spin out its diabetes program into a wholly-owned subsidiary to explore partnerships and funding opportunities, aiming to expedite the development of innovative treatments [3] - The diabetes gene therapy approach utilizes an AAV vector to deliver Pdx1 and MafA genes to the pancreas, showing promise in transforming alpha cells into functional beta-like cells in Type 1 diabetes models [4] Group 3: Market Position and Collaborations - The company is observing the popularity of GLP-1 agonists like Novo Nordisk's Ozempic® and is considering future collaborations in gene therapy for diabetes [2] - Genprex collaborates with world-class institutions to enhance its pipeline of gene therapies, focusing on providing novel treatment options for patients with limited alternatives [4]
Genprex Announces Formation of Mesothelioma Clinical Advisory Board
Prnewswire· 2024-09-19 13:29
Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma AUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program. The Board is comprised of four world-reno ...
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Prnewswire· 2024-09-09 13:29
Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma AUSTIN, Texas, Sept. 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Canc ...
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
Prnewswire· 2024-09-04 13:29
Core Viewpoint - Genprex, Inc. plans to create a new subsidiary focused on diabetes gene therapy, GPX-002, while retaining its oncology programs, aiming to enhance focus and attract investment in both areas [1][2][3]. Company Strategy - The separation of the diabetes program into a new subsidiary, NewCo, is intended to increase interest and expedite clinical development for GPX-002, a gene therapy for Type 1 and Type 2 diabetes [2][3]. - Genprex aims to streamline its oncology clinical development program alongside the diabetes initiative, demonstrating a commitment to focused strategies and research prioritization [3]. Product Development - GPX-002 is designed to transform pancreatic alpha cells into functional beta-like cells to produce insulin, with preclinical studies showing promising results in restoring normal blood glucose levels [4][6]. - The gene therapy approach for Type 2 diabetes involves rejuvenating exhausted beta cells, with the potential to disrupt traditional diabetes treatments [5][8]. Market Context - As of 2024, approximately 38.4 million Americans have diabetes, with projections indicating a rise to 643 million globally by 2030 [9]. - The diabetes market has seen significant health expenditures, totaling approximately $966 billion in 2021, reflecting a 316% increase over the past 15 years [9]. Research and Collaboration - Preclinical data presented at the ATTD 2023 conference highlighted GPX-002's therapeutic potential, showing decreased insulin requirements and improved glucose tolerance in animal models [7]. - Genprex collaborates with the University of Pittsburgh for the development of GPX-002, leveraging academic research to optimize its clinical candidates [4][10].
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Prnewswire· 2024-09-03 12:15
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, Sept. 3, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in September 2024. Event: H.C. Wainwright 26th Annual Global Investment Conference Conferen ...
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
Prnewswire· 2024-08-15 13:30
Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes Video Highlights Recent Oncology Clinical Development Program Updates AUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study upda ...
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
Prnewswire· 2024-08-14 13:25
Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in Acclaim-3 Re-focuses Oncology Clinical Development Program and Advances Work to Establish Biomarkers to Enrich Clinical Trial Patient Populations AUSTIN, Texas, Aug. 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today annou ...
Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
Prnewswire· 2024-08-13 12:31
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors AUSTIN, Texas, Aug. 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Singapore Patent Office has granted a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in c ...
Genprex to Present at the August Sidoti Microcap Conference
Prnewswire· 2024-08-08 12:30
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, Aug. 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming Sidoti M ...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
Prnewswire· 2024-06-27 12:31
Company Achieves Multiple Clinical Development Milestones in 2024 "Genprex continues to make progress across a number of areas critical to advancing our novel gene therapies in oncology and diabetes," said Ryan Confer, President and Chief Executive Officer. "So far this year, we have opened enrollment and have begun treating patients in two new lung cancer clinical trials, while we continued to treat patients in a third lung cancer clinical trial. We have partnered with a large network of community-based on ...